8 unknown, 5 recruiting, 3 completed, 2 not yet recruiting. 11 Phase 2, 8 Phase 1, 2 Phase 3, 1 Not applicable.
Follow Ovarian Clear Cell Carcinoma: new trials by email Literature Review of Ovarian Clear Cell Carcinoma trials Research Report on Ovarian Clear Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TR115 in ARID1A-Mutated Advanced Solid Tumors TR115 - Ovarian Clear Cell Carcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Tarapeutics Science Inc. | 50 | 2026-09-20 | 2026-08-28 |
| Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer Sacituzumab tirumotecan, Pembrolizumab - Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer | Phase 2 | Recruiting | Tufts Medical Center | 50 | 2026-09-01 | 2026-09-16 |
| Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma Treatment - Ovarian Cancer, Ovarian Clear Cell Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 36 | 2026-01-01 | 2025-11-20 |
| INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma QL1706 (bispecific antibody targeting PD-1 and CTLA-4), Bevacizumab, carboplatin - Ovarian Clear Cell Carcinoma | Phase 3 | Recruiting | Tongji Hospital | 226 | 2025-11-15 | 2026-05-18 |
| Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 Dostarlimab, LB-100 - Ovarian Clear Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 21 | 2023-11-10 | 2026-06-23 |
| A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary physician's choice of chemotherapy, immune checkpoint inhibitor based therapy - Ovarian Clear Cell Carcinoma | Unknown | Tongji Hospital | 150 | 2023-03-01 | 2024-08-13 | |
| Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma Zimberelimab, Metformin Hydrochloride - Ovarian Clear Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Fudan University | 20 | 2023-03-01 | 2023-03-08 |
| AMT-151 in Patients With Selected Advanced Solid Tumours AMT-151 - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Unknown | Multitude Therapeutics Inc. | 30 | 2023-01-25 | 2023-10-19 |
| A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma Camrelizumab - Ovarian Clear Cell Carcinoma | Not applicable | Unknown | Peking University Third Hospital | 20 | 2022-10-30 | 2022-11-01 |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas APG-5918 - Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer | Phase 1 | Unknown | Ascentage Pharma Group Inc. | 90 | 2022-09-30 | 2022-11-16 |
| Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer Lenvatinib, Pembrolizumab - Ovarian Clear Cell Carcinoma, Gynecologic Cancer | Phase 2 | Active not recruiting | Elizabeth K. Lee MD | 30 | 2022-09-23 | 2025-12-16 |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin - Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer | Phase 3 | Recruiting | Genelux Corporation | 186 | 2022-08-31 | 2026-08-26 |
| A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer NXP800 - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Terminated | Nuvectis Pharma, Inc. | 45 | 2021-12-31 | 2026-08-06 |
| Asian Multicenter Prospective Study of ctDNA Sequencing NGS analysis of ctDNA - Cervical Cancer, Ovarian Clear Cell Carcinoma | Unknown | National Cancer Center, Japan | 506 | 2021-11-01 | 2024-09-04 | |
| Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma Sintilimab, Bevacizumab Biosimilar IBI305 - Ovarian Clear Cell Carcinoma | Phase 2 | Completed | Tongji Hospital | 38 | 2021-04-07 | 2024-08-13 |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas Tulmimetostat, Enzalutamide - Advanced Solid Tumor, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 300 | 2019-09-18 | 2026-08-19 |
| A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas durvalumab, standard chemotherapy - Ovarian Clear Cell Carcinoma | Phase 2 | Unknown | National University Hospital, Singapore | 46 | 2017-10-09 | 2018-05-18 |
| A Study of PLX2853 in Advanced Malignancies. PLX2853 - Small Cell Lung Cancer, Uveal Melanoma | Phase 1 | Completed | Opna Bio LLC | 49 | 2017-09-12 | 2022-07-25 |
| A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma CDX-014 - Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma | Phase 1 | Terminated | Celldex Therapeutics | 16 | 2016-06-01 | 2020-06-04 |
| Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Nintedanib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD) - Ovarian Clear Cell Carcinoma, Endometrial Clear Cell Carcinoma | Phase 2 | Unknown | NHS Greater Glasgow and Clyde | 120 | 2015-04-01 | 2016-08-15 |
Showing 20 of 21. Sign in to see all of them.
Ovarian Neoplasms (7) · Endometrial Neoplasms (4) · Neoplasms (4) · Lymphoma, Non-Hodgkin (3) · Carcinoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Mesothelioma, Malignant (2) · Nasopharyngeal Carcinoma (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Adenocarcinoma, Clear Cell (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1)
Neoplasms by Site (10) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Genital Diseases (9) · Genital Diseases, Female (9) · Genital Neoplasms, Female (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Neoplasms (8) · Adnexal Diseases (7) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Gonadal Disorders (7) · Neoplasms by Histologic Type (7) · Neoplasms, Glandular and Epithelial (7)
Paclitaxel (3) · Bevacizumab (2) · Carboplatin (2) · liposomal doxorubicin (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Biosimilar Pharmaceuticals (1) · CTLA-4 Antigen (1) · Cisplatin (1) · Docetaxel (1) · Doxorubicin (1) · ENMD 2076 (1) · LB100 (1) · Metformin (1) · Therapeutics (1)
Tongji Hospital (3) · Ascentage Pharma Group Inc. (1) · Celldex Therapeutics (1) · Elizabeth K. Lee MD (1) · Fudan University (1) · Genelux Corporation (1) · M.D. Anderson Cancer Center (1) · Multitude Therapeutics Inc. (1) · NHS Greater Glasgow and Clyde (1) · National Cancer Center, Japan (1) · National University Hospital, Singapore (1) · Novartis Pharmaceuticals (1) · Nuvectis Pharma, Inc. (1) · Opna Bio LLC (1) · Peking University Third Hospital (1)
United States (9) · China (5) · United Kingdom (3) · Singapore (2) · South Korea (2) · Australia (1) · Canada (1) · France (1) · Italy (1) · Japan (1) · Malaysia (1) · Philippines (1) · Poland (1) · Spain (1) · Taiwan (1)
Amir Jazaeri, M D (1) · Amit Oza, M.D. (1) · Catherine Shannon (1) · David SP Tan (1) · Elizabeth K Lee, MD (1) · Hongyan Guo, Doctor (1) · Huaiwu Lu (1) · Jermaine Coward (1) · Kan Yonemori, MD, PhD (1) · Libing Xiang (1) · Mihitha Ariyapperuma (1) · Richardson Gary (1) · Robert W. Holloway, MD (1) · Rosalind Glasspool (1)
PMID 32472319, PMID 32591370, PMID 34686353, PMID 35613822, PMID 37185961, PMID 37227734, PMID 37666539, PMID 38932511, PMID 39276785
2023 (1)